Loading patent…
AssigneeThe University of Liverpool
InventorsMarco Norman Giardiello, Thomas Oliver McDonald, Andrew Owen, Steven Paul Rannard, Philip John Martin, Darren Lee Smith, James Long
Estimating the term…
The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV).
A solid lopinavir composition, comprising nanoparticles of lopinavir dispersed within a mixture of at least one hydrophilic polymer and at least one surfactant;
A solid lopinavir composition comprising:
An aqueous dispersion, comprising a plurality of nanoparticles dispersed in an aqueous medium, the nanoparticles comprising a core of lopinavir and a coating of at least one hydrophilic polymer and at least one surfactant;
(canceled)
(canceled)
Dependencies are inferred from the claim text.